Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System (SNDS)

Author:

Havet A.12ORCID,Bouvard C.1ORCID,Moskal A.1ORCID,Chanelière M.13,Massardier J.4,Lebrun‐Vignes B.5ORCID,Jonville‐Bera A.‐P.6ORCID,Payet C.12,Viprey M.12ORCID

Affiliation:

1. Research on Healthcare Performance (RESHAPE), INSERM U1290 Université Claude Bernard Lyon 1 Lyon France

2. Hospices Civils de Lyon Service Des Données de Santé Lyon France

3. Collège Universitaire de Médecine Générale Université Lyon 1 Villeurbanne France

4. Service de Gynécologie‐Obstétrique Hospices Civils de Lyon, Hôpital Femme‐Mère‐Enfant Lyon France

5. Service de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Pitié‐Salpêtrière, AP‐HP GH Sorbonne Université Paris France

6. Centre Régional de Pharmacovigilance, CHRU de Tours Hôpital Bretonneau Tours France

Abstract

AbstractBackgroundDespite the French pregnancy prevention program (PPP), a considerable number of pregnancies are potentially exposed to oral isotretinoin. New measures were taken by the French Medicines Agency, including the restriction of initial isotretinoin prescriptions to dermatology specialists in May 2015 and a new information campaign on teratogenicity in January 2019.ObjectivesThe aims were to: describe, between 2014 and 2021, compliance with PPP recommendations: isotretinoin use as a second‐line treatment, first prescription by a dermatology specialist, monthly prescription renewal and pregnancy testing (PT); assess the effect of the 2015 and 2019 measures on PT compliance; and identify the determinants of PT noncompliance.MethodsA retrospective cohort study was conducted among women aged 11–50 years initiating isotretinoin between 2014 and 2021 using the French Health Data System. PT compliance corresponded to pregnancy test completion and specific delays between prescription and dispensation. Time series analyses were performed to evaluate the effect of the 2015 and 2019 measures on PT compliance, and log‐binomial and Poisson multivariate regression models were used to identify the determinants of PT noncompliance.ResultsIsotretinoin was prescribed as a second‐line treatment in 64% of initiations, mainly by dermatology specialists (92%). A new monthly prescription was observed in 98% of dispensations. PT compliance reached 61%, 72% and 25% at initiation, renewals and end of treatment, respectively. The 2015 measure was associated with better PT compliance at initiation and renewals. The 2019 measure had no significant effect on PT compliance at the initiation or end of treatment but was associated with a decrease in PT compliance at renewals. Age, low socioeconomic level, initiation by a nondermatology specialist and during summer were associated with PT noncompliance.ConclusionsUnderstanding factors associated with PT noncompliance could help to target specific subpopulations of women treated with isotretinoin.

Funder

Agence Nationale de Sécurité du Médicament et des Produits de Santé

Publisher

Wiley

Reference38 articles.

1. Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin

2. Teratogenic effect of isotretinoin in both fertile females and males (Review);Draghici CC;Exp Ther Med,2021

3. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris

4. Isotretinoin: controversies, facts, and recommendations

5. ANSM.Restriction de la prescription initiale de l'isotrétinoïne orale aux dermatologues. [cited 2022 Oct 17]. Available from:https://archiveansm.integra.fr/S‐informer/Points‐d‐information‐Points‐d‐information/Restriction‐de‐la‐prescription‐initiale‐de‐l‐isotretinoine‐orale‐aux‐dermatologues‐Point‐d‐Information

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3